Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin.

Trial Profile

Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Tanespimycin; Trastuzumab
  • Indications Advanced breast cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Kosan Biosciences
  • Most Recent Events

    • 11 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Nov 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 11 Nov 2009 Planned number of patients changed from 50 to 57 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top